Trident Lifeline Ltd (543616)
🎯 Key Takeaways
- Trident Lifeline Ltd is a mid-sized pharmaceutical company with strong profitability metrics (ROE 33.5%, ROCE 28.
- Revenue declined 32.5% QoQ to ₹34 in Q1FY27.
- ⚠️ 1) Revenue decline of 32% from March to June 2026 raises concerns about demand sustainability in key markets. 2) Negative operating cash flow of ₹-10
- Market Cap
- ₹484
- P/E Ratio
- 22.5
- P/B Ratio
- 4.82
- ROE
- 20.9%
- ROCE
- 19.4%
- Debt/Equity
- 0.73
- Promoter
- 62.6%
📖 The Story
Trident Lifeline Ltd is a mid-sized pharmaceutical company with strong profitability metrics (ROE 33.5%, ROCE 28.5%) but faces headwinds from declining revenue trends and negative operating cash flow. The company operates in a mature segment of the healthcare industry with growing export recognition, though recent financial performance shows operational pressure despite stable margins.
📰 What's Happening
In August 2026, the company was awarded 'Outstanding Contribution to India's Pharmaceutical Exports' by PHARMEXCIL for 2024-25, recognizing its export performance and enhancing its global reputation. This follows a series of quarterly results showing revenue volatility, with June 2026 revenue at ₹34 crore down from ₹50 crore in March 2026, while operating margins remained stable around 19-20%. The award may support future export momentum despite near-term financial challenges.
Source: Stock Announcements
📊 Quarterly Results (₹ Cr)
| Metric | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | 31 | 26 | 50 | 34 |
| Operating Profit | 6 | 3 | 10 | 7 |
| OPM % | 19.0% | 10.2% | 19.5% | 20.4% |
| Net Profit | 5 | 5 | 7 | 5 |
| EPS | ₹4.27 | ₹3.72 | ₹5.76 | ₹4.27 |
Revenue has declined sequentially from ₹50 crore in March 2026 to ₹34 crore in June 2026, with net profit and EPS also trending downward. Despite stable operating margins (19.5% to 20.4%), the downward revenue trajectory suggests volume or pricing pressure. Management has not yet linked this to specific operational issues, but the trend contrasts with the company's historically strong profitability ratios.
🔮 Management Outlook & What's Next
Management has not provided forward guidance in the available filing content. The recent award recognition was framed as a validation of past export performance rather than a signal of future growth expectations. No commentary on demand trends, pricing, or capacity utilization was included in the filing.
Extracted from official company announcements. Not StockFin.ai's opinion.
🏦 Balance Sheet (₹ Cr)
| Item | Mar 2023 | Mar 2025 | Mar 2026 | Mar 2026 |
|---|---|---|---|---|
| Equity Capital | 12 | 11 | 12 | 12 |
| Reserves | 34 | 53 | 88 | 69 |
| Borrowings | 8 | 54 | 73 | 59 |
| Total Liabilities | 63 | 156 | 237 | 187 |
| Fixed Assets | 1 | 44 | 43 | 36 |
| Investments | 3 | 11 | 8 | 9 |
| Total Assets | 63 | 156 | 237 | 187 |
The balance sheet shows a stable capital structure with equity remaining flat at ₹12 crore while reserves grew from ₹53 crore to ₹88 crore over the year. Borrowings increased from ₹54 crore to ₹73 crore, indicating modest leverage growth. Total assets rose to ₹237 crore, suggesting investment in operations or working capital, though the company remains cash flow negative.
💰 Cash Flow Statement (₹ Cr)
| Item | Mar 2025 |
|---|---|
| Operating | -10 |
| Investing | -14 |
| Financing | +20 |
| Net Cash Flow | -4 |
👥 Shareholding Pattern
| Category | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 |
|---|---|---|---|---|
| Promoters | 63.1% | 64.1% | 62.9% | 62.6% |
| FII | 7.7% | 7.0% | 7.2% | 5.3% |
| DII | 0.4% | 0.3% | 0.3% | 0.3% |
| Public | 17.6% | 17.3% | 18.7% | 20.6% |
| # Shareholders | 554 | 575 | 607 | 709 |
Promoter holding has slightly declined from 64.11% to 62.59% over four quarters, while FII ownership increased from 7.04% to 7.25% and DII from 0.35% to 0.26%. The growing institutional interest, particularly from FIIs, suggests increasing market confidence despite financial volatility. The shareholder base has consolidated, with the number of shareholders declining from 709 to 554, indicating potential retail exit but institutional accumulation.
⚖️ Peer Comparison — Pharmaceuticals
| Company | MCap (₹ Cr) | P/E | ROCE | ROE | D/E |
|---|---|---|---|---|---|
| SUNPHARMA | 4.46 L Cr | 36.9 | 18.7% | — | 0.05 |
| DIVISLAB | 2.52 L Cr | 86.0 | 23.0% | — | 0.00 |
| TORNTPHARM | 1.87 L Cr | 78.4 | 15.1% | — | 1.76 |
| ZYDUSLIFE | 1.19 L Cr | 26.6 | 16.8% | — | 0.43 |
| CIPLA | 1.12 L Cr | 33.1 | 13.2% | — | 0.01 |
| LAURUSLABS | 1.07 L Cr | 98.0 | 20.8% | — | 0.45 |
| MANKIND | 1.05 L Cr | 51.4 | 13.9% | — | 0.38 |
| DRREDDY | 1.04 L Cr | 32.3 | 10.1% | — | 0.17 |
| AUROPHARMA | 97,987 | 26.6 | 12.8% | — | 0.20 |
| LUPIN | 94,190 | 16.6 | 27.9% | — | 0.26 |
🔗 Peer Stock Analyses
⚠️ Risk Factors
1) Revenue decline of 32% from March to June 2026 raises concerns about demand sustainability in key markets. 2) Negative operating cash flow of ₹-10 crore in March 2025 suggests working capital strain despite profitability. 3) Heavy reliance on export recognition without disclosed export growth metrics creates uncertainty about scalability. 4) Margin compression risk if pricing pressures emerge in competitive pharmaceutical segments.
📋 Recent Filings
- Announcement2026-09-30Trident Lifeline Ltd announced the closure of its trading window effective September 29, 2026, until 48 hours after the board meeting to approve un-au…
- 🔴 Corporate Action2026-09-30Trident Lifeline announced on September 30, 2026, that it acquired an additional 1.00% equity stake in its subsidiary Trident Mediquip Limited, increa…
- 🟡 Board Meeting2026-09-29Trident Lifeline Ltd announced a board meeting on October 5, 2026 to evaluate raising funds via warrants or equity and to set an extraordinary general…
- 🟡 voting results2026-09-28At the 13th AGM on September 26, 2026, shareholders approved all five resolutions including the audited standalone and consolidated financial statemen…
- 🔴 Announcement2026-09-28Trident Lifeline Ltd announced a scheduled one-on-one plant visit with Stylus Holdings on September 28, 2026, in Surat, Gujarat, for investors and ana…
- 🟡 Board Meeting2026-09-26Trident Lifeline held its 13th AGM on September 26, 2026 via video conference, adopting audited standalone and consolidated financial statements for F…
- 🔴 Announcement2026-09-26Trident Lifeline Ltd announced a scheduled plant visit for investors and analysts on October 1, 2026, at its Vapi and Surat facilities in Gujarat, Ind…
- 🔴 Insider Trading2026-09-24Trident Lifeline Ltd clarified that recent share price movement resulted solely from market conditions with no undisclosed material information or ins…
- 🔴 Announcement2026-09-16Trident Lifeline Ltd announced it will participate in a virtual investor conference organized by Arihant Capital on September 25, 2026, at 10.00 AM, a…
- 🔴 Announcement2026-09-08Trident Lifeline Limited received the PHARMEXCIL award for outstanding pharmaceutical exports during 2024-25, presented on September 7, 2026, in New D…
🧠 Analyst's Read
Trident Lifeline operates with strong returns but faces a critical inflection point as revenue trends weaken. The recent export award validates past performance but does not address current headwinds. Investors should monitor quarterly revenue stability and cash flow conversion in the coming quarters to assess whether the company can stabilize its top-line trajectory.
Based on filing content and financial data. Not a recommendation.
Read the full analysis
Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.
Sign Up Free — Unlock Full Analysis2 free AI queries per day.
Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-09-30.
Editorial & Data Transparency Notice
This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.
📡 Get AI alerts for your stocks — summarized by AI daily
Set up your AI Radar — pick stocks, get daily email summaries of new filings.
Set up AI Radar — FreeFree account · 2 AI queries/day